Aims/hypothesis. Maturity onset diabetes of the young type 3 (MODY3) is a monogenic form of diabetes mellitus caused by mutations in the gene encoding for hepatocyte nuclear factor 1 alpha, HNF1α. In this study we have examined the in vivo and in vitro effects of a mutation (L107I) outside the DNA binding and dimerization domains in the N terminal part of the HNF1α gene. Methods. Beta-cell function of the affected family members was assessed by an oral glucose tolerance test. Functional tests were carried out to explain the role of the mutation in vitro by transcriptional activity assay, Western blotting, DNA-binding assays and subcellular localization experiments. Results. Affected family members showed an 86% decreased insulin response to glucose when compared to age-matched healthy control subjects. In vitro the mutation showed a 79% decrease in transcriptional activity as compared to wild type HNF1α in HeLa cells lacking HNF1α. The transcriptional activity was not suppressed when the mutant was co-expressed with wild type HNF1α suggesting that the decreased activity was not mediated by a dominant negative mechanism. The L107I/HNF1α protein showed normal nuclear targeting but impaired binding to an HNF1α consensus sequence. Conclusion/interpretation. Our results suggest that the L107I substitution represents a MODY3 mutation which impairs beta-cell function by a loss-of-function mechanism. [Diabetologia (2002) 
pha (HNF1α) [2] [3] [4] [5] [6] [7] . HNF1α is a homeodomain containing transcription factor expressed in several tissues including the liver, kidney, pancreas and gut [8, 9, 10] . The protein regulates a number of liver specific genes as well as genes involved in glucose metabolism (e.g. L-type pyruvate kinase) and glucose transport (e.g. GLUT2) [11, 12] . HNF1α is composed of three known functional domains: an N-terminal dimerization domain (amino acids 1-32), a DNA-binding domain with pseudo-Pou and homeodomain motifs (amino acids 150-280) and a C-terminal transactivation domain (amino acids 281-631) [13] . The function of the region between amino acids 100-150 is not entirely clear but could be involved in DNA recognition [14] . HNF1α binds to DNA as a homodimer or heterodimer with the structurally related HNF1β protein [15] . Although mutations associated with MODY3 Maturity onset diabetes of the young (MODY) is a monogenic form of diabetes mellitus with autosomal dominant inheritance. It is characterised by early onset and impaired insulin secretion with minimal or no defect in insulin action [1] . There are at least six different types of MODY, MODY3 being the most common form resulting from mutations in the gene encoding the transcription factor hepatocyte nuclear factor 1 alhave been found in all regions of the HNF1α including the promoter region most of them seem to affect the DNA binding domain and particularly a mutational hotspot in exon 4 [16, 17] . The relation between the location of the mutations and the MODY3 phenotype is not straightforward. Proteins with amino acid substitutions inhibiting DNA-binding have been shown to form non-functional homodimers with the wild-type protein, either by haplo-insufficiency or dominantnegative mechanisms [13] . Whether there is a relation between the MODY3 genotype and phenotype, i.e. whether there are "milder" mutations outside the DNA binding domain, is a hypothesis that is open to question. To address this, we investigated the biological consequences of a mutation at codon 107, between the dimerization and DNA binding domain in the HNF1α gene, which segregates with diabetes in a Swedish MODY family.
Materials and methods
In vivo studies: subjects. A family from southern Sweden carrying a mutation causing a substitution of leucine with isoleucine (L107I) in the HNF1α gene has been described previously [18] . The family included eight mutation carriers in three generations.
Subjects were challenged by a 75 g oral glucose tolerance test (OGTT). Blood samples for measurements of plasma glucose and serum insulin concentrations were drawn at -5, 0, 30, 60 and 120 min. We used the insulin over glucose ratio as a measure of the insulin response at a given glucose concentration. For three patients requiring insulin therapy, no OGTT was carried out and beta-cell function was instead assessed as insulin/C-peptide response 6 min after i.v. injection of 0.5 mg glucagon [19] . Plasma glucose was measured with a glucose oxidase method using a Beckman Glucose Analyzer II (Beckman Instruments, Fullerton, Calif., USA) and insulin was measured with ELISA (DAKO, Cambridgeshire, UK) with an interassay CV of 8.9%. Age-matched non-diabetic subjects (n=66) and patients with Type II (non-insulin-dependent) diabetes mellitus (n=48) without MODY mutations served as control subjects for the OGTT. Data from eight non-diabetic subjects were used as reference values for the glucagon test. Fasting blood samples were drawn for measurements of serum total cholesterol, HDL-cholesterol and triglycerides. To calculate waist-to-hip ratio, waist circumference was measured midway between the lowest rib and the iliac crest and hip circumference was measured over the widest part of the glutereal region. For blood pressure records the mean of three measurements were calculated after 30 min of rest at 5-min intervals. Studies were approved by local ethics committees.
In vitro studies: plasmid constructs. In vitro mutagenesis was carried out on full-length human HNF1α cDNA using a QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, Calif., USA). The oligo-nucleotide used in mutagenesis was 5′-GCCGTGGTGGAGACCATTCTGCAGGAGGACC-3′, with the mutated nucleotide underlined corresponding to the L107I substitution. Wild type and mutant HNF1α were subcloned into a pcDNA3.1 expression vector (Invitrogen, NV Leek, Netherlands). Sequences of the created constructs were verified by DNA sequencing before expression studies. Western blot analysis. 1.2×10 6 HeLa cells and 2.8×10 6 MIN6 cells were transfected using Lipofectamine plus Reagent (Life Technologies) with 5 µg of wild type or mutant HNF1α-pcDNA3.1 construct. After 24 h, whole cell extracts were prepared using RIPA lysis buffer (50 mmol/l Tris-HCl (pH 8), 150 mmol/l NaCl, 1% NP-40, 0.5% deoxycolate, 1 mmol/l sodiumorthovanadate, 15 µg/ml aprotinin, 1 mmol/l phenylmethylsulphonyl fluoride). 5 µg of total protein was subjected to SDS-PAGE (10%) and transferred to Hybond-P membranes (Amersham Pharmacia Biotech, Uppsala, Sweden). After blocking the membranes for 1.5 h with 5% milk powder and 0.05% Tween-20 in Tris buffered saline, the membranes were incubated with anti-HNF1α(N-19) (Santa Cruz Biotechnology, Santa Cruz, Calif., USA) or anti-HNF1 (BD Bioscience, San Diego, Calif., USA) for 1 h followed by a horseradish peroxidase conjugate anti-goat IgG (Santa Cruz Biotechnology) or anti-mouse IgG (Amersham Biosciences AB, Uppsala, Sweden) for 1 h. The antibody binding was visualized using Supersignal West Pico Chemiluminescent Substrate (Pierce, Rockford, Ill., USA).
Electrophoretic Mobility Shift Assay (EMSA). 1.2×10 6 HeLa cells were transfected with 5 µg of wild type or mutant HNF1α-pcDNA3.1 using Lipofectamine plus Reagent (Life Technologies). After 24 h, nuclear protein extracts were prepared as previously described [20] and 4.0 µg of extracted proteins were incubated with a 27 bp 32 P-labelled oligonucleotide probe (~50,000 cpm), containing the GLUT2 promoter HNF1α binding site sequence (CTCAGTAAAGATTAACCAT). Samples were incubated at room temperature for 20 min in a buffer containing 10 mmol/l HEPES (pH 7.9), 60 mmol/l KCl, 0.1 mmol/l EDTA, 10% glycerol, 15 mmol/l dithiothreitol and 150 ng poly dI-dC. The complexes were shifted with addition of 1 µl anti-HNF1α(N-19)X (Santa Cruz Biotechnology). The DNA-protein complexes were separated on a 4% polyacrylamide gel and visualized by autoradiography. 
h, respectively. Fluorescence was examined using a fluorescence microscope (TRITC filter) with a digital camera (Nikon Eclipse 800, Nikon, Tokyo, Japan). Statistics. Data are shown as means ± SEM or SD. A p value of less than 0.05 was considered statistically significant. At each time point of the OGTT, statistical comparisons were carried out by Mann-Whitney U test (SAS Institute Inc., Cary, N.C., USA).
The Dual Luciferase assay results were from three independent experiments, each carried out in triplicate; differences were calculated with paired Student's t test.
Results
Clinical characteristics of L107I-carriers. The pedigree of the affected family is shown in Fig. 1 with the age at onset indicated for the diabetic subjects. All mutation carriers developed diabetes between the age of 18 and 38 years. The clinical and anthropometric data from the affected MODY patients, Type II diabetic patients and healthy control subjects are given in Table 1 . The insulin over glucose ratio (calculated from the incremental area) during the OGTT was 86% lower in carriers of the L107I substitution compared to control subjects. At 30, 60 and 120 min of the OGTT the insulin over glucose ratios were reduced (p<0.005) in the L107I-carriers. The differences were not significant between the L107I-carriers and the Type II diabetic patients. As expected, the Type II diabetic patients had a lower insulin/glucose ratio than the control subjects (p<0.005 Fig. 2 ). The incremental insulin responses to glucagon were reduced by 46%, 91% and 82% in the three insulin-treated patients compared with the mean (± SD) of healthy control subjects (58, 9, 20 vs 108±30 pmol/l in control subjects subjects).
Impaired transcriptional activity of HNF1α containing the L107I substitution.
To characterise the functional consequences of the L107I mutation in vitro, we compared the ability of the L107I-HNF1α protein to activate the human GLUT2 promoter with that of the wild type protein. Transcriptional activity of the mutated HNF1α in HeLa cells (lacking endogenous HNF1α) was reduced by 79% compared with the wild type (0.11±0.02 vs 0.51±0.01; p<0.005, Fig. 3A) . In contrast, transcriptional activity was normal when tested in MIN6 cells that express the corresponding mouse HNF1α (Fig. 3B) . To examine whether the mutation could have a dominant-negative effect on wild type HNF1α in HeLa cells, increasing amounts of the L107I-HNF1α were transfected together with 50 ng of wild type HNF1α. No dominant-negative effect was observed (Fig. 3C) . Western blot analysis confirmed equal expression of the mutated and wild type protein (Fig. 4A) . Results are given as means ± SD (6, 7, 8) were compared with 66 agematched control subjects and 48 age-matched diabetic patients (±5 years). Results are given as means ± SEM and * indicates p<0. 005 Nuclear translocation of HNF1α is not impaired by the L107I substitution. To examine whether the L107I substitution affects nuclear translocation of the HNF1α protein we carried out intracellular localization studies using immunostaining. HeLa cells were transfected with either wild type HNF1α or L107I-HNF1α and the subcellular location was assessed by fluorescence microscope (Fig. 6) . The nuclear signals Fig. 3A-C . Transcriptional activation by wild type and mutant HNF1α. Luciferase activity was normalized by the activity of the internal control pRL-TK and the reporter construct contained the GLUT2 promoter. The results were from three independent experiments; means ± SEM, *indicating p<0.005. A HeLa cells transfected with 50 ng wild type, L107I-HNF1α-pcDNA3.1 or empty vector. B MIN6 cells transfected with 100 ng wild type, L107I-HNF1α-pcDNA3.1 or empty vector. C Wild type HNF1α-pcDNA3.1 (50 ng) and L107I-HNF1α-pcDNA3.1 (0, 50, 100, 200 ng) was cotransfected to examine a possible dominant negative effect by the mutated protein. Total amount of DNA added was adjusted to 250 ng with empty vector mutant protein showed lack of DNA binding as depicted in Fig. 5A , although in some experiments minimal binding activity was detected (data not shown). Gel shift specificity was examined using anti-HNF1α antibody, which is shown in Fig. 5A by a clear supershift of the complex. of HeLa cells transfected with wild type or mutated HNF1α did not differ, indicating that the L107I substitution does not impair nuclear translocation. We further confirmed equal expression of both wild type and mutant protein in nuclear extracts by Western blot analysis (Fig. 4B ).
Discussion
The mutation causing the L107I substitution in the HNF1α gene was identified in a typical MODY family with a dominant mode of inheritance and age at onset of diabetes less than 25 years in at least two family members. This substitution has not been described in other MODY families, Type II diabetic patients or in a group of non-diabetic control subjects [18] . No mutations in other MODY genes were observed in the affected family members. It is therefore likely that this mutation caused diabetes in this family [18] . The clinical phenotype was also similar to the phenotype described in MODY3 patients [21] with markedly impaired beta-cell function and normal insulin sensitivity. In addition, their serum lipid profile was much better than that seen in patients with the common form of Type II diabetes.
Substitution of leucine with another nonpolar hydrophobic amino acid isoleucine at codon 107 results in only moderate changes in the primary structure of the HNF1α protein but could theoretically influence its secondary structure as hydrophobic interactions between amino acids are important for protein structures. Moreover, since this amino acid residue has been shown to be conserved between different species [22] it is therefore likely to be important in maintaining the tertiary structure and integrity of the protein. The role of the intermediary region between the dimerization and DNA binding domain, where the L107I substitution is located, remains somewhat elusive but it has been ascribed a role in DNA recognition [14, 23] . Our data clearly showed that a leucine for isoleucine substitution at codon 107 results in impaired DNA binding and reduced transcriptional activity in HeLa cells. It is not likely that decreased transcriptional activity would be a consequence of the experimental conditions as both the mutated and wild type HNF1α showed equal amount of expressed proteins.
In MIN6 cells, in contrast to HeLa cells which do not contain endogenous HNF1α, transcriptional activity was normal suggesting that endogenous HNF1α is able to compensate for the effect of the mutated protein and that the mutation works in a loss-of-function manner. This is most likely due to haploinsufficiency as HeLa cells transfected with increasing amounts of the mutated L107I-HNF1α together with wild type HNF1α did not show impaired transcriptional activity as would be expected if the mutation would operate in a dominant negative manner.
Other studies of mutations in this region, e.g. a P112L substitution show an association with reduced DNA-binding and normal nuclear targeting [24] , while a Y122C substitution shows reduced DNAbinding together with reduced protein content in the nucleus, reduced protein stability but with a correct targeting of HNF1α to the nucleus [25] . The consequences of another nearby variant, substituting an alanine for valine at codon 98 (A98V) is unclear. While some studies have suggested that the frequency of A98V is increased in patients with early onset Type II diabetes [18] and that A98V would be associated with impaired insulin secretion [26] no functional data on this variant is available. Taken together with previous data, our findings with the L107I substitution indicate that at least codons 107-122 are important not only for DNA recognition but also for DNA binding.
In conclusion, we show evidence that a L107I substitution in the HNF1α gene results in loss-of-function of the protein, and that impaired transcriptional activity of this protein is due to impaired DNA binding.
